Lexeo to acquire Mantle for up to $21.3M; adds FA pipeline and collaborations

Lexeo Therapeutics, Inc.

Acquisition: $8.3M upfront (cash+equity) plus up to $13M milestones for Mantle; total potential $21.3M; close expected Q3 2026.
Mantle pipeline adds LX3010 (oral, ~6-pt mFARS improvement, 9x frataxin increase), LX3030, LX3050, LX3070 for FA.
Collaborations: Weill Cornell (cerebellar sequential dosing), Vivet (VTX-PID option), Apertura (CapX capsid option) to support LX2006.
LX2006 SUNRISE-FA 2 topline on track for 2H 2027; CLARITY-FA has 22 participants enrolled/imminently enrolling.
Cash runway into 2028 unchanged; expects to advance one acquired program to clinic and submit an IND in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.